Detalhe da pesquisa
1.
Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.
Br J Cancer
; 130(12): 1990-2002, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38600326